

Claims:

49. A method for expressing a non-polio nucleotide sequence in a cell comprising:
contacting [the] a cell[, **in a physiologically acceptable carrier,**] with an amount of a composition effective to result in [said] expression **of a non-polio nucleotide sequence, said composition** comprising a recombinant polio virus nucleic acid having a **non-polio** nucleotide sequence encoding, in an expressible form, a gene product substituted for at least a portion of the P1 capsid precursor region of the poliovirus genome,
under conditions appropriate for introduction of the recombinant poliovirus nucleic acid into the cell, thereby generating a modified cell which expresses [a] said gene product encoded by said **non-polio** nucleotide sequence.

62. The method of claim 61 [60] wherein the viral gene is an HIV gene.

Specification:

On page 6, line 35, after the end of the sentence add:

--In figure 23B, Thr-Thr-Ala-Lys-Leu-Thr (SEQ ID NO: 24) is the polypeptide sequence at the transition between the encoded signal sequence and CEA. In figure 23C, Met-Gly-Leu-Gu-Lys (SEQ ID NO: 25) is the polypeptide sequence at the transition between the encoded polio and CEA sequences, and Ile-Tyr-Val-Thr-Lys-Asp-Leu-Thr-Thr-Tyr-Gly (SEQ ID NO: 26) is the polypeptide sequence at the transition between the encoded CEA and 2A cleavage sequences.--